Cha Bio Group said on the 21st that it recently held a forum at the Cha Bio Complex in Pangyo, Gyeonggi Province, to share the latest technology trends in cell and gene therapies (CGT). Cell and gene therapies are next-generation medicines that fundamentally cure diseases by modifying a patient's cells or genes. Four hundred people from domestic pharmaceutical and bio corporations, associations, and investment firms attended to discuss investment trends and business strategies.
Cha Bio Group is building a cell and gene therapy complex facility (CGB) in Pangyo's 2nd Techno Valley. It plans to create an innovation center (CGB CIC) there for bio venture corporations. It will support bio corporations with facilities, equipment, investment attraction, new drug development, and product commercialization. The CGB will have a floor area of 20,000 pyeong (66,115 square meters), and the CGB CIC will have a floor area of 3,000 pyeong (10,000 square meters), with operations starting in 2027.
Yang Eun-young, a vice president at Cha Bio Group, said, "CGB CIC is a platform that can perform everything from research and development to commercialization in a one-stop manner." Dennis Medlenka, president of CIC, said, "The jobs created so far by corporations that have moved into CIC exceed 200." CIC is a bio venture innovation hub established in 1999 in Cambridge near Boston in the United States. Earlier, Cha Bio Group signed a business agreement with CIC to build the Pangyo innovation center.
In addition, Ryu Seong-ho, president of the Korea Society for Bioinformatics, Park Min, chief operating officer of Matica Biotechnology, and Professor Chihiro Azakawa (Chihiro Akazawa) of Juntendo University in Japan presented technology trends. A company official said, "We matched biotech corporations and investment firms that had applied in advance and held meetings," adding, "We provided participating corporations with opportunities to attract investment as performance."